MedTrace Logo

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

NCT05256732 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2022-10-18

No results posted yet for this study

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 following oral administration under fasting conditions or with a meal in healthy adult subjects

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

AT-527 fasted

AT-527 administered twice daily (BID) for 5 days fasted

OTHER

Placebo Comparator fasted

Matching placebo administered twice daily (BID) for 5 days fasted

DRUG

AT-527 fed

AT-527 administered twice daily (BID) for 5 days fed

OTHER

Placebo Comparator fed

Matching placebo administered twice daily (BID) for 5 days fed

DRUG

AT-527

AT-527 administered twice daily (BID)

DRUG

AT-527 single dose

AT-527 single dose fasted/fed cross-over

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2022-08-23
Completion
2022-08-23
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256732 on ClinicalTrials.gov